Biogen Raises Full-Year Revenue Guidance as New Drug Business Surpasses Multiple Sclerosis Business for the First Time
Claire Weston
Biogen posted Q2 adjusted EPS of $3.60, beating estimates by over $1.57, on revenue of $2.7 billion — up 3.8% year-on-year. The company flipped its full-year revenue outlook from mid-single-digit decline to mid-single-digit growth, marking the first quarter where newer drugs outsold its legacy MS portfolio.
Why did this quarter surprise the Street?
Adjusted EPS came in at $3.60 — $1.57 above consensus, nearly double what analysts expected.
Revenue hit $2.7 billion, up 3.8% year-on-year, beating estimates by $240 million.
This means → Biogen didn't just "not disappoint." It delivered positive growth in a quarter the market had written off.
How did newer drugs overtake the legacy business?
Biogen closed its $5.6 billion acquisition of Apellis Pharmaceuticals in May, adding Syfovre (for an immune-driven blinding disease) and Empaveli (for rare blood and kidney disorders). The two drugs contributed roughly $128 million in revenue for the partial quarter.
Postpartum-depression treatment Zurzuvae grew 53% year-on-year to $71 million; rare-disease drug Skyclarys posted about $168 million, ahead of analyst estimates.
Alzheimer's drug Leqembi (co-marketed with Eisai) rose 15% to $184 million, roughly in line with expectations.
In plain terms = Biogen shifted from a one-legged revenue model — MS drugs — to a multi-legged one through acquisitions and organic launches. Combined, the newer portfolio now outsells the legacy franchise.
Why did guidance move in opposite directions?
Revenue guidance raised: flipped from "mid-single-digit percentage decline" to "mid-single-digit percentage growth" — a full directional reversal.
EPS guidance cut: lowered from $14.25–$15.25 to $12–$13, driven by R&D costs, milestone payments, and financing expenses tied to the Apellis deal.
This means → Biogen is trading near-term profit for a new revenue engine. Management noted that stripping out acquisition-related items, underlying earnings guidance actually rose by $0.60.
What does the market watch next?
CEO Christopher Viehbacher announced a second deal in June — up to $1 billion for private immunology developer RayThera — expanding into nephrology and immunology.
This reflects a clear strategic bet: the MS franchise is in irreversible decline, so Biogen must build new growth pillars through M&A.
Put simply = whether the newer drugs can sustain volume growth and earn back the acquisition spend is the core test for when Biogen's earnings trajectory recovers.
Content is for reference only, not financial advice.